碘难治性分化型甲状腺癌的精准靶向治疗进展

王新霞; 马腾闯; 崔亚利; 王新霞; 马腾闯; 崔亚利

doi:10.3760/cma.j.issn.1673-4114.2019.06.012

[1]

郑向前, 候秀坤, 高明. 2017年第二版NCCN甲状腺肿瘤指南解读[J]. 中国肿瘤临床, 2018, 45(1): 14-17. doi: 10.3969/j.issn.1000-8179.2018.01.046
Zheng XQ, Hou XK, Gao M. Interpretation of the second edition of the NCCN guidelines for thyroid cancer in 2017[J]. Chin J Clin OncolChin J Clin Oncol, 2018, 45(1): 14-17. doi: 10.3969/j.issn.1000-8179.2018.01.046

[2]

Tang JN, Kong DG, Cui QX, et al. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER[J/OL]. Onco Targets Ther, 2018, 11: 3551[2018-08-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016280/pdf/ott-11-3551.pdf. DOI: 10.2147/OTT.S160752.

[3]

Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013[J]. JAMAJAMA, 2017, 317(13): 1338-1348. doi: 10.1001/jama.2017.2719

[4]

Haugen BR, Sawka AM, Alexander EK, et al. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features[J]. ThyroidThyroid, 2017, 27(4): 481-483. doi: 10.1089/thy.2016.0628

[5]

Berdelou A, Lamartina L, Klain M, et al. Treatment of refractory thyroid cancer[J]. Endocr Relat CancerEndocr Relat Cancer, 2018, 25(4): R209-R223. doi: 10.1530/ERC-17-0542

[6]

林岩松, 黄慧强, 郭晔, 等. 持续/复发及转移性甲状腺癌诊疗指南2018.V1[DB/OL]. [2018-08-29]. https://max.book118.com/html/2019/0329/8070122117002014.shtmhttp://www.doc88.com/p-9783918230133.html.

Lin YS, Huang HQ, Guo Y, et al. PERSISTENT/RECURRENT AND METASTATIC THYROID CANCER[DB/OL]. [2018-08-29]. http://www.doc88.com/p-9783918230133.html.

[7]

Acquaviva G, Visani M, Repaci A, et al. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance[J]. HistopathologyHistopathology, 2018, 72(1): 6-31. doi: 10.1111/his.13380

[8]

Xing MZ. Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer[J]. ThyroidThyroid, 2010, 20(7): 697-706. doi: 10.1089/thy.2010.1646

[9]

Saji M, Ringel MD. The PI3K-AKT-mTOR pathway in initiation and progression of thyroid tumors[J]. Mol Cell EndocrinolMol Cell Endocrinol, 2010, 321(1): 20-28. doi: 10.1016/j.mce.2009.10.016

[10]

Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. LancetLancet, 2014, 384(9940): 319-328. doi: 10.1016/S0140-6736(14)60421-9

[11]

Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer[J]. N Engl J MedN Engl J Med, 2015, 372(7): 621-630. doi: 10.1056/NEJMoa1406470

[12]

Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial[J]. J Clin OncolJ Clin Oncol, 2012, 30(2): 134-141. doi: 10.1200/JCO.2011.35.5040

[13]

Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in Progressive Medullary Thyroid Cancer[J]. J Clin OncolJ Clin Oncol, 2013, 31(29): 3639-3646. doi: 10.1200/JCO.2012.48.4659

[14]

Cabanillas ME, Brose MS, Holland J, et al. A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer[J]. ThyroidThyroid, 2014, 24(10): 1508-1514. doi: 10.1089/thy.2014.0125

[15]

Atallah V, Hocquelet A, Do Cao C, et al. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients[J]. ThyroidThyroid, 2016, 26(8): 1085-1092. doi: 10.1089/thy.2015.0648

[16]

Capdevila J, Trigo JM, Aller J, et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)[J]. Eur J EndocrinolEur J Endocrinol, 2017, 177(4): 309-317. doi: 10.1530/EJE-17-0243

[17]

Lim SM, Chung WY, Nam KH, et al. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer[J]. Eur J CancerEur J Cancer, 2015, 51(12): 1588-1595. doi: 10.1016/j.ejca.2015.05.020

[18]

Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study[J]. Lancet OncolLancet Oncol, 2010, 11(10): 962-972. doi: 10.1016/S1470-2045(10)70203-5

[19]

Brose MS, Cabanillas ME, Cohen EEW, et al. Vemurafenib in patients with BRAF^V600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial[J]. Lancet OncolLancet Oncol, 2016, 17(9): 1272-1282. doi: 10.1016/S1470-2045(16)30166-8

[20]

Falchook GS, Millward M, Hong D, et al. BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer[J]. ThyroidThyroid, 2015, 25(1): 71-77. doi: 10.1089/thy.2014.0123

[21]

Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer[J]. N Engl J MedN Engl J Med, 2013, 368(7): 623-632. doi: 10.1056/NEJMoa1209288

[22]

Liu JW, Chen C, Loh EW, et al. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials[J]. Curr Med Res OpinCurr Med Res Opin, 2017, 34(5): 795-803. doi: 10.1080/03007995.2017.1368466

[23]

Hewett Y, Ghimire S, Farooqi B, et al. Lenvatinib-A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer[J]. J Oncol Pharm PractJ Oncol Pharm Pract, 2018, 24(1): 28-32. doi: 10.1177/1078155216680119

[24]

林岩松, 王宸, 李慧, 等. 甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告[J]. 中国癌症杂志, 2016, 26(9): 721-726. doi: 10.19401/j.cnki.1007-3639.2016.09.001
Lin YS, Wang C, Li H, et al. The preliminary report about the efficacy and safety evaluation of apatinib in progressive radioactive iodine-refractory differentiated thyroid cancer within 8 weeks[J]. China OncolChina Oncol, 2016, 26(9): 721-726. doi: 10.19401/j.cnki.1007-3639.2016.09.001

[25]

Lin YS, Wang C, Gao W, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer[J/OL]. Oncotarget, 2017, 8(26): 42252−42261[2018-08-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522064/pdf/oncotarget-08-42252.pdf. DOI: 10.18632/oncotarget.15036.

[26]

Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial[J]. Lancet OncolLancet Oncol, 2012, 13(9): 897-905. doi: 10.1016/S1470-2045(12)70335-2

[27]

Narayanan S, Colevas AD. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer[J]. Curr Treat Options OncolCurr Treat Options Oncol, 2016, 17(6): 30-. doi: 10.1007/s11864-016-0404-6

[28]

黄美玲, 李永平, 凌瑞. BRAF^V600E基因突变与乳头状甲状腺癌淋巴结转移相关性的Meta分析[J]. 中国肿瘤, 2017, 26(2): 145-151. doi: 10.11735/j.issn.1004-0242.2017.02.A014
Huang ML, Li YP, Ling R. A Meta-analysis on the Correlation Between BRAF^V600E Gene Mutation and Lymph Nodes Metastasis in Papillary Thyroid Carcinoma[J]. China CancerChina Cancer, 2017, 26(2): 145-151. doi: 10.11735/j.issn.1004-0242.2017.02.A014

[29]

Takeshita A, Taguchi M, Koibuchi N, et al. Putative Role of the Orphan Nuclear Receptor SXR (Steroid and Xenobiotic Receptor) in the Mechanism of Cyp3a4 Inhibition by Xenobiotics[J]. J Biol ChemJ Biol Chem, 2002, 277(36): 32453-32458. doi: 10.1074/jbc.M111245200

[30]

Fröhlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture[J]. Endocr Relat CancerEndocr Relat Cancer, 2005, 12(2): 291-303. doi: 10.1677/erc.1.00973

[31]

Henriques de Figueiredo B, Godbert Y, Soubeyran I, et al. Brain Metastases from Thyroid Carcinoma: A Retrospective Study of 21 Patients[J]. ThyroidThyroid, 2014, 24(2): 270-276. doi: 10.1089/thy.2013.0061

[32]

Orita Y, Sugitani I, Matsuura M, et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma[J]. SurgerySurgery, 2010, 147(3): 424-431. doi: 10.1016/j.surg.2009.10.009

[33]

林岩松, 杨雪. 碘难治性甲状腺癌的诊治进展[J]. 中国癌症杂志, 2017, 27(6): 442-450. doi: 10.19401/j.cnki.1007-3639.2017.06.008
Lin YS, Yang X. Research progress in diagnosis and treatment of radioiodine-refractory differentiated thyroid cancer[J]. China OncolChina Oncol, 2017, 27(6): 442-450. doi: 10.19401/j.cnki.1007-3639.2017.06.008

[34]

Besic N, Dremelj M, Pilko G. Locoregional disease control after external beam radiotherapy in 91 patients with differentiated thyroid carcinoma and pT4 tumor stage-a single institution experience[J]. Radiol OncolRadiol Oncol, 2018, 52(4): 453-460. doi: 10.2478/raon-2018-0038

[35]

Dupuy DE, Monchik JM, Decrea C, et al. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy[J]. SurgerySurgery, 2001, 130(6): 971-977. doi: 10.1067/msy.2001.118708

[36]

Czepczyński R, Matysiak-Grześ M, Gryczyńska M, et al. Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity[J]. Arch Immunol Ther ExpArch Immunol Ther Exp, 2015, 63(2): 147-154. doi: 10.1007/s00005-014-0318-6

[37]

张蓉琴, 尹吉林, 王欣璐, 等. 靶向生长抑素受体正电子显像剂的临床研究进展[J]. 中国医学影像学杂志, 2015, 23(8): 627-631. doi: 10.3969/j.issn.1005-5185.2015.08.018
Zhang RQ, Yin JL, Wang XL, et al. Advances in clinical studies of positron imaging agents targeting somatostatin receptors[J]. Chin J Med ImagingChin J Med Imaging, 2015, 23(8): 627-631. doi: 10.3969/j.issn.1005-5185.2015.08.018

[38]

Budiawan H, Salavati A, Kulkarni HR, et al. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using ⁹⁰Yttrium and ¹⁷⁷Lutetium labeled somatostatin analogs: toxicity, response and survival analysis[J/OL]. Am J Nucl Med Mol Imaging, 2013, 4(1): 39−52[2018-08-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867728/pdf/ajnmmi0004-0039.pdf.

[39]

Versari A, Sollini M, Frasoldati A, et al. Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients[J]. ThyroidThyroid, 2014, 24(4): 715-726. doi: 10.1089/thy.2013.0225

[40]

Naoum GE, Morkos M, Kim B, et al. Novel targeted therapies and immunotherapy for advanced thyroid cancers[J/OL]. Mol Cancer, 2018, 17(1): 51[2018-08-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817719/pdf/12943_2018_Article_786.pdf. DOI: 10.1186/s12943-018-0786-0.

[41]

Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy[J]. Nat Rev Clin OncolNat Rev Clin Oncol, 2016, 13(5): 273-290. doi: 10.1038/nrclinonc.2016.25

[42]

Bastman JJ, Serracino HS, Zhu Y, et al. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2016, 101(7): 2863-2873. doi: 10.1210/jc.2015-4227

[43]

Mehnert JM, Varga A, Brose M, et al. Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study[J]. J Clin OncolJ Clin Oncol, 2016, 34(S15): S6091-.

[44]

Mahoney KM, Freeman GJ, McDermott DF. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma[J]. Clin TherClin Ther, 2015, 37(4): 764-782. doi: 10.1016/j.clinthera.2015.02.018

[45]

Ryder M, Gild M, Hohl TM, et al. Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression[J/OL]. PLoS One, 2013, 8(1): e54302[2018-08-29]. https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0054302&type=printable. DOI: 10.1371/journal.pone.0054302.

[46]

Zwaenepoel K, Jacobs J, De Meulenaere A, et al. CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy[J]. HistopathologyHistopathology, 2017, 71(3): 357-365. doi: 10.1111/his.13230

[47]

Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J/OL]. Oncotarget, 2016, 7(22): 32318−32328[2018-08-29]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078015/pdf/oncotarget-07-32318.pdf. DOI: 10.18632/oncotarget.8698.

[48]

Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev CancerNat Rev Cancer, 2016, 16(5): 275-287. doi: 10.1038/nrc.2016.36

[49]

Faugeras L, Pirson AS, Donckier J, et al. Refractory thyroid carcinoma: which systemic treatment to use?[J]. Ther Adv Med OncolTher Adv Med Oncol, 2018, 10: 1758834017752853-. doi: 10.1177/1758834017752853